Reduced risk of heart disease by 20%! Novo Nordisk A/S's (NVO.US) weight loss drug, Wegovy, has won a new indication in the European Union.
The European Medicines Agency (EMA) supports the use of Wegovy to reduce the risk of major cardiovascular disease and stroke in overweight or obese adults.
EC Conditionally Approves Pfizer's Haemophilia B Gene Therapy
How To Earn $100 Per Month From Pfizer Stock
Pfizer Options Spot-On: On July 25th, 837.97K Contracts Were Traded, With 2.78 Million Open Interest
Pandion Optimization Alliance Celebrates Excellence at 2nd Annual GOAT Awards
Express News | CNBC Halftime Report Final Trades: Freeport-McMoRan, Pfizer, Danaher, United Rentals
